55442-07-4

Usage

Uses

Used in Pharmaceutical Industry:
Custanolide is used as a potential therapeutic agent for various conditions due to its anti-inflammatory, anti-tumor, and neuroprotective properties. It is being investigated for its potential in treating cardiovascular diseases and osteoporosis.
Used in Research and Development:
Custanolide is used as a subject of ongoing research to explore its potential therapeutic applications and to further understand its pharmacological properties. This research can lead to the development of new drugs and treatments based on custanolide's unique chemical structure and effects.

Upstream product

• 112-24-3 triethylentetramine 
• 98-59-9 p-toluenesulfonyl chloride 
• 4556-90-5 N-(2-bromo-ethyl)-4-methyl-benzenesulfonamide 
• 4403-78-5 ditosylethylenediamine 
• 7732-18-5 water 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 52601-75-9 1,4,7,10,13,16-hexa(4-methylphenylsulfonyl)-1,4,7,10,13,16-hexaazacyclooctadecane 
• 99892-24-7 (mesyl-1-tetratosyl-4,7,10,13)-pentaaza-1,4,7,10,13-cyclopentadecane 
• 52667-88-6 cyclen tetratosylate 
• 81582-18-5 1,4,7,10-tetrakis(toluene-p-sulphonyl)-1,4,7,10-tetra-azacyclotetradecane 
• 52601-74-8 N¹,N⁴,N⁷,N¹⁰,N¹³-pentatosyl-1,4,7,10,13-penta-azacyclopentadecane 
• 135839-86-0 14,15-dibromo-2,5,8,11-tetrakis(p-tolylsulphonyl)-1,2,3,4,5,6,7,8,9,10,11,12-dodecahydrobenzo<1,4,7,10>tetraazacyclotetradecine 
• 71089-73-1 1,4,7,10-tetra(p-tosyl)-1,4,7,10-tetraazacyclotridecane 
• 229031-05-4 6,9,12,15-tetrakis-(toluene-4-sulfonyl)-5,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-6,9,12,15-tetraaza-dibenzo[a,c]cyclohexadecene 
• 106471-25-4 N³,N⁶,N⁹,N¹²-tetratosyl-3,6,9,12-tetraaza-1,14-tetradecanediol 
• 865102-57-4 N,N',N'',N'''-tetratosyl-2,5,8,11-tetraaza[12]metacyclophane 
• 60147-33-3 4,7,10,13-tetrakis-(toluene-4-sulfonyl)-1-oxa-4,7,10,13-tetraaza-cyclopentadecane 

Relevant academic research and scientific papers

Superalkali-Alkalide Interactions and Ion Pairing in Low-Polarity Solvents

The nature of anionic alkali metals in solution is traditionally thought to be "gaslike"and unperturbed. In contrast to this noninteracting picture, we present experimental and computational data herein that support ion pairing in alkalide solutions. Concentration dependent ionic conductivity, dielectric spectroscopy, and neutron scattering results are consistent with the presence of superalkali-alkalide ion pairs in solution, whose stability and properties have been further investigated by DFT calculations. Our temperature dependent alkali metal NMR measurements reveal that the dynamics of the alkalide species is both reversible and thermally activated suggesting a complicated exchange process for the ion paired species. The results of this study go beyond a picture of alkalides being a "gaslike"anion in solution and highlight the significance of the interaction of the alkalide with its complex countercation (superalkali).

High-efficiency environment-friendly low-cost synthetic method of cycleanine

The invention discloses a high-efficiency environment-friendly low-cost synthetic method of cycleanine. The synthetic method comprises the following steps: step a, mixing triethylene tetramine, water,potassium carbonate and acetone to obtain a mixture, separately adding paratoluensulfonyl chloride into the mixture in different batches, and synthesizing a compound 2; step b, adding the compound 2and 1,2-dibromoethane into a solvent, and synthesizing a compound 3 in the presence of alkaline metal carbonate; step c, adding water and sulfuric acid into the compound 3, adding ethanol into a reaction product, precipitating, discharging, centrifuging, collecting a solid product, adding water and active carbon into the solid product, stirring, decoloring, centrifuging, collecting filtrate, adding hydrochloric acid, perfor ming salting-out crystallization, precipitating, discharging, centrifuging, collecting the solid product, and obtaining a compound 4; and step d, taking the compound 4 andan alkaline substance as raw materials, synthesizing a cycleanine crude product, extracting and purifying by virtue of methylbenzene-water, and obtaining the cycleanine. The high-efficiency environment-friendly low-cost synthetic method has the advantages of low cost, high efficiency, environmental friendliness.

Synthesis of an azacrown template for phosphatidylinositol-4,5-bis(phosphate) recognition

An azacrown system has been developed for selective membrane binding of phosphatidylinositol-4,5-bis(phosphate) recognition. Neutral and cationic forms of the metacyclophane macrocycles have been synthesized by divergent routes in acceptable yields. Such

Preparation and animal biodistribution of 166Ho labeled DOTA for possible use in intravascular radiation therapy (IVRT)

Owing to its favorable decay characteristics (T1/2 = 27 h, Eβ(max) = 1.85 MeV, Eγ = 81 keV) and its availability with a specific activity of 3.74.4GBq/mg from a moderate flux reactor, 166Ho can be considered as a potential radionuclide for intravascular radiation therapy (IVRT) using liquid-filled balloons. In the present work, studies on the use of 166Ho labeled 1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as a possible agent for IVRT for the prevention of restenosis has been initiated. 166Ho was obtained by irradiating natural Ho2O3 powder and DOTA was synthesized by a multistep procedure. The optimum protocol of radiolabeling of DOTA with 166Ho was achieved by varying different reaction parameters. The complex was found to retain its stability for 7 days at room temperature. Bioevaluation studies carried out in Wistar rats showed that >95% of the injected activity was excreted within 3 h p.i. with almost no retention in any major organ. Both radiochemical and biological studies showed that 166Ho labeled DOTA can be further explored as a potential agent for IVRT. Copyright

Preparation of hexaaza and heptaaza macrocycles functionalized with a single aminoalkyl pendant arm

A practical and reproducible route for the preparation of 1,4,7,10,13,16,19-heptaazacyclohenicosane (1), 1,4,7,10,13,16-hexaazacyclooctadecane (2), and 1,4,7,10,13,17-hexaazacycloicosane (3) bearing a single N-(2-amino-ethyl) pendant arm has been develope

Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

1,4,7,10,13,16,19,22-Octaazacyclotetracosane-l,4,7,10,13,16,19,22- octaacetic acid (H8OTEC) and 1,4,7,10,14,17,20,23-octaazacyclohexacosane-1,4,7,10,14,17,20,23-octaacetic acid (H8OHEC): Synthesis and characterization of two large macrocyclic p

The optimized synthesis of two new macrocyclic polyamine polycarboxylic ligands, 1,4,7,10,14,17,20,23-octaazacyclohexacosane-1,4,7,10,14,17,20,23-octaaceticacid (H8OHEC) (10) 1 and 1,4,7,10,13,16,19122-octaazacyclotetracosane-1,4,7,10, 13,16,19

Methods of preparing manganese complexes of nitrogen-containing macrocyclic ligands

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Synthesis and characterization of various unsubstituted and mono-N-substituted tetraazamacrocycles

Syntheses of tetraazamacrocycles have been carried out by using p-toluenesulfonyl chloride as protective group.The and were also obtained by the template synthesis.Mono-N-functionalization of tetraazamacrocycles was accomplished by reaction of a fivefold excess of the free macrocycles with 1 equivalent of a suitable alkylating or arylating reagent.The key point of the synthesis lies in the use of an excess of the macrocycle over the substituting reactants to reduce the formation of polysubstituted derivatives, and in the easy separation of the excess of unreacted macrocycle.All the products were characterized on the basis of spectral studies (1H and 13C NMR, including 2D NMR and NOE difference studies) and mass spectrometry.Key words: tetraazamacrocycles, improved synthesis, protective group, N-tosylation, template synthesis, NOE difference spectroscopy.